Hannah J Vaughan
Overview
Explore the profile of Hannah J Vaughan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaughan H, Est-Witte S, Dockery L, Urello M, Boyd J, Keyser B, et al.
Sci Technol Adv Mater
. 2024 May;
25(1):2351791.
PMID: 38817250
Targeted nanoparticles offer potential to selectively deliver therapeutics to cells; however, their subcellular fate following endocytosis must be understood to properly design mechanisms of drug release. Here we describe a...
2.
Vaughan H, Zamboni C, Luly K, Li L, Gabrielson K, Hassan L, et al.
Int J Nanomedicine
. 2023 May;
18:2525-2537.
PMID: 37197026
Purpose: Hepatocellular carcinoma (HCC) has limited treatment options, and modest survival after systemic chemotherapy or procedures such as transarterial chemoembolization (TACE). There is therefore a need to develop targeted therapies...
3.
Vaughan H, Zamboni C, Hassan L, Radant N, Jacob D, Mease R, et al.
Sci Adv
. 2022 Jul;
8(29):eabo6406.
PMID: 35857843
Hepatocellular carcinoma (HCC) develops predominantly in the inflammatory environment of a cirrhotic liver caused by hepatitis, toxin exposure, or chronic liver disease. A targeted therapeutic approach is required to enable...
4.
Vaughan H, Green J
Curr Opin Biomed Eng
. 2021 Nov;
20.
PMID: 34738046
There is great interest in developing gene therapies for many disease indications, including cancer. However, successful delivery of nucleic acids to tumor cells is a major challenge, and efficacy is...
5.
Vaughan H, Zamboni C, Radant N, Bhardwaj P, Lechtich E, Hassan L, et al.
Mol Ther Oncolytics
. 2021 Jun;
21:377-388.
PMID: 34189258
Despite initial promise, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based approaches to cancer treatment have yet to yield a clinically approved therapy, due to delivery challenges, a lack of potency, and...
6.
Kim J, Vaughan H, Zamboni C, Sunshine J, Green J
J Control Release
. 2021 Jun;
337:105-116.
PMID: 34097924
Successful systemic gene delivery requires specific tissue targeting as well as efficient intracellular transfection. Increasingly, research laboratories are fabricating libraries of novel nanoparticles, engineering both new biomaterial structures and composition...
7.
Vaughan H, Green J, Tzeng S
Adv Mater
. 2019 Jun;
32(13):e1901081.
PMID: 31222852
Nucleic acids are a promising type of therapeutic for the treatment of a wide range of conditions, including cancer, but they also pose many delivery challenges. For efficient and safe...
8.
Kozielski K, Ruiz-Valls A, Tzeng S, Guerrero-Cazares H, Rui Y, Li Y, et al.
Biomaterials
. 2019 Apr;
209:79-87.
PMID: 31026613
Novel treatments for glioblastoma (GBM) are urgently needed, particularly those which can simultaneously target GBM cells' ability to grow and migrate. Herein, we describe a synthetic, bioreducible, biodegradable polymer that...
9.
Karlsson J, Vaughan H, Green J
Annu Rev Chem Biomol Eng
. 2018 Mar;
9:105-127.
PMID: 29579402
Polymeric nanoparticles have tremendous potential to improve the efficacy of therapeutic cancer treatments by facilitating targeted delivery to a desired site. The physical and chemical properties of polymers can be...
10.
Zamboni C, Kozielski K, Vaughan H, Nakata M, Kim J, Higgins L, et al.
J Control Release
. 2017 Mar;
263:18-28.
PMID: 28351668
Hepatocellular carcinoma (HCC) is the third most deadly cancer in the US, with a meager 5-year survival rate of <20%. Such unfavorable numbers are closely related to the heterogeneity of...